# Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)

> **NCT03216538** · PHASE1,PHASE2 · COMPLETED · sponsor: **Feramda** · enrollment: 20 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** AS101 1% oral solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03216538
- **Lead sponsor:** Feramda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-08
- **Primary completion:** 2020-05-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03216538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03216538, "Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03216538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*